COVID-19 Impact : Monocyte Activation Test Market Exploring Future Growth 2019-2030 - Merck, Thermo Fisher Scientific, Becton

Monocyte activation testing is the test that detects the presence of pyrogens (an element produced by bacterium that triggers fever in the body) in pharmaceutical products and all the medical devices. Pryogens are the harmful substances derived from microorganisms, inducing fever in animals and humans. When a pryogen enters in a bloodstream, it induces natural immunity that causes fever due to cytokines. Monocyte activation test (MAT) is capable of identifying endotoxin and non-endotoxin pyrogens, both in one single test. This test is supported by several regulatory bodies, and the MAT itself is strong enough to generate sensitive results dependent on human immune reaction.

The growing pandemic of corona virus has significantly impacted the extensive use of monocyte activation test. The rising number of positive cases of corona virus, across the globe gave rise to the use of this testing. Owing to the ability of recognizing and potential of the test to detect early symptoms in positive patients is devoted to the clinical utility. Wider use of monocyte activation test has disclosed crucial details in patients. These include presence of larger than normal monocytes that are easily detected on forward scatter and side scatter examination by regular flow cytometry. This also includes the presence of a different population of monocytes having high forward scatter.

Major Key Players of the Monocyte Activation Test Market are:Merck, Thermo Fisher Scientific, Becton, Dickinson and Company, Sanquin, Charles River Laboratories International, Inc., Microcoat Biotechnologie GmbH, SOLVIAS AG and Lonza Group among others.